Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia

Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia

Background: Ustekinumab was approved in 2016 for the treatment of moderate–severe Crohn’s disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologic...

Full description

Bibliographic Details
Main Authors: Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M. Smith, Andrew Plumb, Farooq Z. Rahman
Format: Article
Language:English
Published: SAGE Publishing 2023-08-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/20406223231189072

Internet

https://doi.org/10.1177/20406223231189072

Similar Items